Member of European Parliament Isabella Tovaglieri and Chairman of the Health Commission of Lombardy Region Emanuele Monti led delegation to visit NMS Group in Nerviano, Lombardy
Nerviano, 7 February 2022 NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of...NMS Group S.p.A. announces appointment of New CEO Hugues Dolgos and New Board of Directors and CEO of its Subsidiaries
Nerviano, 17 January 2022 The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are...
Entrectinib, the kinase inhibitor drug invented and initially developed by Nerviano Medical Sciences won the Prix Galien Italia 2021 Award in the Chemically Synthesized Drugs category
Nerviano, 5 November 2021 Entrectinib, the kinase inhibitor drug that was invented and initially developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has won the Prix Galien Italia 2021 award as an...Nerviano Medical Sciences Receives FDA “Study May Proceed” Letter for First-In-Human Phase 1 Clinical Trial under Its Investigational New Drug Application for NMS-03602173, a Dual IDH1/2 Inhibitor, in Advanced Solid Tumors
Nerviano, 22 October 2021 Nerviano Medical Sciences (NMS Srl,) a member of NMS Group and a pharmaceutical company developing innovative new chemical entities (NCE) for the treatment of cancers, today announces that the U.S. Food and Drug Administration...
Welcome and Check out our new motion picture!
Recent Comments